Health news
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Aficamten is an investigational oral, selective, small molecule cardiac myosin inhibitor designed to reduce…
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Aficamten is an investigational oral, selective, small molecule cardiac myosin inhibitor designed to reduce…
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application for empagliflozin to reduce the risk of cardiovascular (CV) death plus hospitalization for heart failure (HF) in adults with…
Among patients with cardiovascular diseases who have received an implantable cardiac assistive device, women, individuals with lower income, and those who are divorced are at increased risk for having a more difficult time adjusting to…
CaroSpir (spironolactone oral suspension) 25mg/5mL is now available in a unit dose cup. The Food and Drug Administration (FDA) approved CaroSpir in August 2017 for adults who have difficulty swallowing or who cannot swallow tablets.…
Women with heart failure (HF) are significantly more likely to be physically frail compared with men with HF, according to research results published in Circulation: Heart Failure. Because 1 of every 2 patients with HF…
The Food and Drug Administration (FDA) granted Breakthrough Therapy designation to empagliflozin for the treatment of adults with heart failure with preserved ejection fraction. The designation is based on data from the randomized, double-blind, phase…
The widespread use of dapagliflozin for treating heart failure (HF) with reduced ejection fraction (HFrEF) has the potential to improve long-term clinical outcomes and may be a cost-effective treatment, according the a recent study published…
Full results from the phase 3 EMPEROR-Preserved trial showed that treatment with empagliflozin demonstrated significant risk reduction of cardiovascular death or hospitalization for heart failure in adults with heart failure and preserved ejection fraction. The…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021